Nuvation Bio Inc. Financing Cash Flow
Nuvation Bio Inc. (NUVB) reported Financing Cash Flow of $170.57 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- Nuvation Bio Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $170.53M, a 11.84% decline year-over-year.
- Nuvation Bio Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $44.00K, a 91.97% decline year-over-year.
- Nuvation Bio Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $8.06M.
- Nuvation Bio Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $501.00K.
- Nuvation Bio Inc. net cash provided by (used in) financing activities for fiscal 2025 was $202.53M, a 61088.82% increase from fiscal 2024.
- Nuvation Bio Inc. net cash provided by (used in) financing activities for fiscal 2024 was $331.00K, a 47.29% decline from fiscal 2023.
- Nuvation Bio Inc. net cash provided by (used in) financing activities for fiscal 2023 was $628.00K, a 52.68% decline from fiscal 2022.
- Nuvation Bio Inc. net cash provided by (used in) financing activities for fiscal 2022 was $1.33M, a 99.79% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 2 month | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 5 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 8 month | Net Cash Provided by (Used in) Financing Activities 8 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $170.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $170.57M 10-Q · filed 2026-08-06 | $178.64M derived: sum of 3 quarters · filed 2026-08-06 | $179.14M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $44.00K 10-Q · filed 2026-05-04 | $8.11M derived: sum of 2 quarters · filed 2026-05-04 | $8.61M derived: sum of 3 quarters · filed 2026-05-04 | $202.03M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $8.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $8.56M derived: sum of 2 quarters · filed 2026-03-02 | $201.99M derived: sum of 3 quarters · filed 2026-08-06 | $202.53M 10-K · filed 2026-03-02 | ||||
| 2025-09-30 | $501.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $193.92M derived: sum of 2 quarters · filed 2026-08-06 | $194.47M 10-Q · filed 2025-11-03 | $193.57M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $193.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $193.97M 10-Q · filed 2026-08-06 | $193.07M derived: sum of 3 quarters · filed 2026-08-06 | $191.53M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $548.00K 10-Q · filed 2026-05-04 | -$352.00K derived: sum of 2 quarters · filed 2026-05-04 | -$1.89M derived: sum of 3 quarters · filed 2026-05-04 | $858.00K derived: sum of 4 quarters · filed 2026-05-04 | ||||
| 2024-12-31 | -$900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$2.44M derived: sum of 2 quarters · filed 2026-03-02 | $310.00K derived: sum of 3 quarters · filed 2026-03-02 | $331.00K 10-K · filed 2026-03-02 | ||||
| 2024-09-30 | -$1.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $1.21M derived: sum of 2 quarters · filed 2025-11-03 | $1.23M 10-Q · filed 2025-11-03 | $1.35M derived: sum of 4 quarters · filed 2025-11-03 | ||||
| 2024-06-30 | $2.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.77M 10-Q · filed 2025-08-07 | $2.89M derived: sum of 3 quarters · filed 2025-08-07 | $2.97M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | $21.00K 10-Q · filed 2025-05-07 | $141.00K derived: sum of 2 quarters · filed 2025-05-07 | $218.00K derived: sum of 3 quarters · filed 2025-05-07 | $351.00K derived: sum of 4 quarters · filed 2025-05-07 | ||||
| 2023-12-31 | $120.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $197.00K derived: sum of 2 quarters · filed 2025-03-06 | $330.00K derived: sum of 3 quarters · filed 2025-03-06 | $628.00K 10-K · filed 2025-03-06 | ||||
| 2023-09-30 | $77.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $210.00K derived: sum of 2 quarters · filed 2024-11-06 | $508.00K 10-Q · filed 2024-11-06 | $915.00K derived: sum of 4 quarters · filed 2024-11-06 | ||||
| 2023-06-30 | $133.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $431.00K 10-Q · filed 2024-08-05 | $838.00K derived: sum of 3 quarters · filed 2024-08-05 | $1.10M derived: sum of 4 quarters · filed 2024-08-05 | ||||
| 2023-03-31 | $298.00K 10-Q · filed 2024-05-14 | $705.00K derived: sum of 2 quarters · filed 2024-05-14 | $963.00K derived: sum of 3 quarters · filed 2024-05-14 | -$2.64M derived: sum of 4 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | $407.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $665.00K derived: sum of 2 quarters · filed 2024-02-29 | -$2.94M derived: sum of 3 quarters · filed 2024-02-29 | $1.33M 10-K · filed 2024-02-29 | ||||
| 2022-09-30 | $258.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$3.34M derived: sum of 2 quarters · filed 2023-11-02 | $920.00K 10-Q · filed 2023-11-02 | $1.46M derived: sum of 4 quarters · filed 2023-11-02 | ||||
| 2022-06-30 | -$3.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $662.00K 10-Q · filed 2023-08-03 | $1.20M derived: sum of 3 quarters · filed 2023-08-03 | $1.17M derived: sum of 4 quarters · filed 2023-08-03 | ||||
| 2022-03-31 | $4.26M 10-Q · filed 2023-05-04 | $4.80M derived: sum of 2 quarters · filed 2023-05-04 | $4.77M derived: sum of 3 quarters · filed 2023-05-04 | $4.83M derived: sum of 4 quarters · filed 2023-05-04 | ||||
| 2021-12-31 | $538.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $506.00K derived: sum of 2 quarters · filed 2023-03-15 | $563.00K derived: sum of 3 quarters · filed 2023-03-15 | $625.53M 10-K · filed 2023-03-15 | ||||
| 2021-09-30 | -$32.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $25.00K derived: sum of 2 quarters · filed 2022-11-03 | $624.99M 10-Q · filed 2022-11-03 | $757.62M derived: sum of 4 quarters · filed 2022-11-03 | ||||
| 2021-06-30 | $57.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $625.02M 10-Q · filed 2022-08-04 | $757.66M derived: sum of 3 quarters · filed 2022-08-04 | $758.16M derived: sum of 4 quarters · filed 2022-08-04 | ||||
| 2021-03-31 | $624.96M 10-Q · filed 2022-05-09 | $757.60M derived: sum of 2 quarters · filed 2022-05-09 | $758.10M derived: sum of 3 quarters · filed 2022-05-09 | |||||
| 2020-12-31 | $132.63M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $133.13M derived: sum of 2 quarters · filed 2022-02-28 | $145.54M 10-K/A · filed 2021-05-21 | $145.36M 10-K · filed 2021-03-11 | $133.13M 10-K · filed 2022-02-28 | |||
| 2020-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $145.58M 10-Q · filed 2020-11-16 | $500.00K 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | $3.38K 10-Q · filed 2020-08-14 | $0.00 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |